Unlikely to cause harm — often a labeling or packaging issue.
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
| Brand name | EPTIFIBATIDE |
| Generic name | EPTIFIBATIDE |
| Active ingredient(s) | EPTIFIBATIDE |
| Distributed by / for | Slate Run Pharmaceuticals, LLC, Columbus, Ohio 43215 |
| Full product label | Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL Single-dose Vial, For Intravenous Use Only, Rx Only, Manufactured by: Hainan Poly Pharm. Co., Ltd., Guilinyang Economic Development Area, Haikou, Hainan Province, China 571127; Distributed by: Slate Run Pharmaceuticals, LLC, Columbus, Ohio 43215. NDC Slate Run Carton Label: 70436-027-80; NDC ProRx Carton Label: 70436-163-80 |
| Recalling firm | Slate Run Pharmaceuticals |
| Distribution | Nationwide within the USA. |
| Quantity | N/A |
| Recall initiated | 2026-02-12 |
| Report date | 2026-03-04 |
| Recall completed | — |
| Recall number | D-0343-2026 |
| Classification | Class III |
| FDA status | Ongoing |
| Origin on file | Columbus OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗